Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Insulin, ultra-short acting (insulin aspart, insulin glulisine, insulin lispro)

Generic name
Insulin, ultra-short acting (insulin aspart, insulin glulisine, insulin lispro)
Brand name
ATC Code
A10AB04

Pharmacokinetics in children

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Diabetes mellitus, insulin-dependent
  • Subcutaneous
    • 1 month up to 18 years
      • Dose depending on the blood sugars


      • Treatment by or after consulting a paediatric specialist (paediatric endocrinologist) who has experience of using insulins.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

The insulin requirement may be decreased in cases of reduced renal function. The dosage is adjusted depending on the blood glucose measurements in this case.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Side effects in children are similar to side effects in adults. Injection site lipodystrophy is seen more often in children than in adults. 

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Insulins and analogues for injection, fast-acting
A10AB01
Insulins and analogues for injection, intermediate-acting
A10AC01
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
A10AD06
A10AD01
Insulins and analogues for injection, long-acting
A10AE

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Novo Nordisk A/S, SPC Novorapid (EU/1/99/119/001;008; 015) 03-02-2016, www.ema.europa.eu, http://www.ema.europa.eu/docs/nl_NL/document_library/EPAR_-_Product_Information/human/000258/WC500030372.pdf
  3. Sanofi-Aventis Deutschland GmbH, SPC Apidra (EU/1/04/285/001-004) 26-04-2010, www.geneesmiddeleninformatiebank.nl
  4. Eli Lily Nederland BV, SPC Humalog (EU/1/96/007/008) 28-10-2014, www.geneesmiddeleninformatiebank.nl
  5. Novo Nordisk A/S, SmPC Fiasp (EU 1/16/1160/001-011)26-08-2019
  6. Informatorium Medicamentorum, (Interacties), Geraadpleegd 16 juni 2016
  7. ZorgInstituut Nederand, Farmacotherapeutisch Kompas (Eigenschappen, Contra-Indicaties, Bijwerkingen, Waarschuwingen en Voorzorgen), Geraadpleegd 16 juni 2016
  8. Informatorium Medicamentorum, (Interacties), Geraadpleegd 16 juni 2016
  9. ZorgInstituut Nederand, Farmacotherapeutisch Kompas (Eigenschappen, Contra-Indicaties, Bijwerkingen, Waarschuwingen en Voorzorgen), Geraadpleegd 16 juni 2016
  10. ZorgInstituut Nederand, Farmacotherapeutisch Kompas (Eigenschappen, Contra-Indicaties, Bijwerkingen, Waarschuwingen en Voorzorgen), Geraadpleegd 16 juni 2016
  11. Informatorium Medicamentorum, (Interacties), Geraadpleegd 16 juni 2016

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes